Yann Neuzillet
Overview
Explore the profile of Yann Neuzillet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
3336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Houede N, Chevallier T, Audenet F, Thibault C, Neuzillet Y, Abraham C, et al.
J Clin Oncol
. 2025 Feb;
:JCO2500179.
PMID: 39951246
Purpose: After radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-risk patients. This study evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin +...
2.
Choukroun R, Tayeh G, Pinar U, De Kerviler E, Mongiat Artus P, Verine J, et al.
Fr J Urol
. 2024 Dec;
35(2):102839.
PMID: 39643042
Objective: Renal oncocytoma is a benign renal tumour whose management remains heterogeneous and poorly codified. The aim of this study was to describe the management strategies and evolution of a...
3.
Roumiguie M, Seisen T, Masson-Lecomte A, Prost D, Allory Y, Xylinas E, et al.
Fr J Urol
. 2024 Nov;
34(12):102722.
PMID: 39581669
Introduction: The purpose of this study was to propose an update of the French guidelines from the national committee ccAFU on upper tract urothelial carcinomas (UTUC). Methods: A systematic Medline...
4.
Roumiguie M, Leon P, Xylinas E, Allory Y, Audenet F, Bajeot A, et al.
Fr J Urol
. 2024 Nov;
34(12):102742.
PMID: 39581667
Objective: To update the CCAFU recommendations for the management of non-muscle invasive bladder cancer (NMIBC). Methods: A systematic review (Medline) of the literature from 20222024 was performed, taking into account...
5.
Roumiguie M, Marcq G, Neuzillet Y, Bajeot A, Allory Y, Sargos P, et al.
Fr J Urol
. 2024 Nov;
34(12):102741.
PMID: 39581664
Objective: To update the CCAFU recommendations for the management of muscle-invasive bladder cancer (MIBC). Methods: A systematic review (Medline) of the literature from 2022 to 2024 was carried out, taking...
6.
Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, et al.
Nat Commun
. 2024 Oct;
15(1):9370.
PMID: 39478018
No abstract available.
7.
Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, et al.
Nat Commun
. 2024 Oct;
15(1):8603.
PMID: 39366934
Metastatic urothelial carcinoma (mUC) is a lethal cancer, with limited therapeutic options. Large-scale studies in early settings provided critical insights into the genomic and transcriptomic characteristics of non-metastatic UC. The...
8.
Guilbert A, Lebret T, Oudard S, Audenet F, Thibault C, Gervais C, et al.
Fr J Urol
. 2024 Sep;
34(13):102744.
PMID: 39299560
Introduction: In 2022, nivolumab was granted marketing authorization for adjuvant treatment in patients at high-risk of recurrence following surgery for localized invasive muscle urothelial carcinoma, who express PD-L1 on the...
9.
Neuzillet Y, Raynaud J, Dreyfus J, Radulescu C, Rouanne M, Schneider M, et al.
Eur Urol Oncol
. 2024 Aug;
PMID: 39209681
Background And Objective: Failure rates after first-line treatment of localized prostate cancer (PCa) treatment remain high; therefore, it is essential to improve the selection and identification of at-risk patients to...
10.
Mesnard B, Glorion M, Jalal Eddine A, Roux A, Branchereau J, Neuzillet Y, et al.
Ann Transplant
. 2024 Aug;
29:e944049.
PMID: 39182171
BACKGROUND End-stage renal disease is a major issue in the management of patients undergoing lung transplantation. Combined kidney-lung transplantation (CKLT) and kidney after lung transplantation (KALT) are the 2 preferred...